Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (3149)	12/4/1997 8:43:00 PM
From: Izzy	Read Replies (2) \| Respond to of 6136

Did Johnson indicate what the expected sales/revenues would be from EU Viracept sales? It appears to me that the Rhinovirus PI clinical studies will not start until the end of 1998. If so, there probably could not be another commercial product before 2000. In fact, it seems like AGPH will not have another product on the market until 2001. That is, there is an excellent potential pipeline coming but no additional revenues, besides Viracept, for several years. Also, it is not clear to me if Viracept will actually be marketed in Africa/Asia where the drug is obviously needed but is not affordable. Yet, even with Viracept alone, the stock should be worth >50/sh. Any comments?